Numerous studies have supported the importance of immunity to SAG1, the most predominant antigen of Toxoplasma tachyzoite, in protection against Toxoplasma gondii infection. Nevertheless, vaccination with SAG1 provides insufficient protection when compared with that of Toxoplasma lysate (TL). In order to screen the Toxoplasma antigens for immunogenic potential shown by modified protection or induction of specific immune response after infection, recombinant antigens were prepared in Eschericha coli using DNA fragments corresponding to SAG1, SAG2, SAG3, SRS1 and P54 of T. gondii RH strain maintained in our laboratory. Each of the recombinant antigen products or a mixture of the five antigens (Mix) was used to vaccinate mice. Mice then received a lethal dose of T. gondii. Up to 25% of the mice vaccinated with SAG2, SRS1, P54 and Mix survived, whereas there were no survivors in gene 10-(negative control), SAG1-and SAG3-vaccinated groups. In all the survivors, brain cysts were not observed. Conversely, vaccination with TL almost completely protected mice in the acute phase but permitted brain cyst formation and resulted in gradual decrease of survivors to 33% during 4 months of experiments. Western blot analysis on convalescent sera showed an extensive IgG induction to a 30 kDa antigen in TL-vaccinated mice, a 22 kDa in SAG2-vaccinated mice and a 55 kDa in P54-vaccinated mice. The protection modified by boost in specific antibody is suggestive of the immunogenic potential of SAG2, SRS1 and possibly P54 against T. gondii infection.
Toxoplasma gondii is a widespread pathogenic parasite. The commonest mode of transmission of the parasite to humans is through ingestion of cysts developed in the muscular tissue of farm animals [1, 2, 12, 28] . Live vaccines containing useful mutants of the parasite can reduce abortion and persistent infection in farm animals [8, 14, 21, 29, 30] . However, these vaccines have not been widely accepted because of the associated side effects [15] , a short shelf life and high costs. The live vaccines also carry risk of accidental infection to humans and unexpected harmful reverse mutation. To overcome these problems, subunit and recombinant vaccines are a trend in recent research for the development of a vaccine against T. gondii.
Protective immunity generated by primary infection with T. gondii can completely protect the host against subsequent infections. Convalescent sera reasonably contain immunoglobulins that react to immunogenic antigens. The convalescent sera show extensively predominant reaction to SAG1 (surface antigen 1 or P30, [3] ), a key mediator of attachment to host cells [9] . Then the studies for immunogenic antigens of T. gondii have been concentrated on SAG1. Anti-SAG1 antibodies reduce parasite invasion to host cells in vitro [9, 20] . Vaccination with native SAG1 saved genetically resistant A/J mice by 66% and susceptible C57BL mice by 33% against lethal infection of T. gondii [11] . Baculovirus produced SAG1 prolonged mice survival from 2 to 3 weeks [6] . The most efficient recombinant SAG1 increased mice survival from 1/5 to 5/9 on day 11 [20] .
Hehl et al. have predicted the redundancy of SAG1 by other functionally related proteins on the parasite surface [10] . The reduction of attachment by SAG1 defective mutation was no more than 40% [16] . Therefore, antigens that can induce specific reactions and modify the protection are helpful tools in investigation for the development of recombinant vaccines against Toxoplasma. In order to screen such antigens, we examined 5 recombinant antigens corresponding to Toxoplasma SAG1, SAG2 [22] , SAG3 [4] , SRS1 [10] and P54 [23] derived from RH strain maintained in our laboratory. SAG2 is a major surface antigen known as an attachment ligand [9] . SAG3 is a major surface antigen structurally related to SAG1 with 24% overall amino acid identity [4] . SRS1 is a minor antigen containing partially common structure to SAG1 and transclipted by SAG1 promoter [10] . P54 is identified through a screening for strong stimulation to Toxoplasma-reactive T-cell clone indicated by high level IFN-γ production [23] . We produced each recombinant antigen in E. coli and immunized mice with it. The mice then challenged with T. gondii bradyzoites.
MATERIALS AND METHODS
Toxoplasma strains: Two strains of Toxoplasma gondii were used for this study. The RH strain tachyzoites were maintained in vitro culture on HS68 cells as previously described [27] . The Beverley strain bradyzoites were harvested from brain homogenates of infected mice by density gradient centrifugation followed by cyst wall digestion with trypsin [17] .
Mice : Specific pathogen free (SPF) female BALB/c mice were purchased from Clea Japan (Shizuoka, Japan). The mice were subjected to the experiment at 8 weeks of age.
Recombinant antigens : SAG1, SAG2, SAG3, SRS1 and P54 coding regions were PCR-amplified from genomic DNA of the RH strain with primers composed of an unique restriction sites (ACGAATTC) and the following antigen specific sequences: TTGTATGTCGGTT and GACGAG-ATGTTT for SAG1; AACTATGAGTTTCT and CTTTTA-CACAAACG for SAG2; CGAGATGCAGCTGT and CATTTAGGCAGCCA for SAG3; GCAAATGGT-GAGGA and ACCTTAGACGGCAC for SRS1; CATG-GAAAACTGTG and TACTCAGAAGTCTC for P54. Then, recombinant antigens were prepared in E. coli with the pGEM expression system (Promega, NY) to produce fusion proteins with gene 10 leader peptide. The fusion proteins were precipitated into the 18,000 × g down pellet from the E. coli lysate prepared by sonication (Ultra S Homogenizer VP15S, Taitech, Japan) and lysozyme (Wako, Japan) treatment. The down pellets were re-suspended and washed three times with phosphate buffered saline (PBS). Contents of the fusion proteins were determined by the density of the SDSPAGE-Coomassie brilliant blue (CBB) staining bands using an image analyzer (Luminous imager 2.0G, Aisin Cosmos, Japan). Each of the encoding genes from E. coli was subcloned into pUC19 (Toyobo, Japan) and sequenced by PRISM cycle sequencing systems (PE Applied Biosystems Japan, Japan).
Toxoplasma lysate (TL) : TL was prepared as previously described [24] . Total protein concentration in TL was quantified with Coomassie Protein Assay Reagent (Pierce, IL).
Immunization: All the antigens were prepared at a concentration of 1 µg/µL with PBS before use. Each experime ntal group c onsis ting of 12 mic e re ce ived 2 intraperitoneal (i.p.) injections of 100 µg/mice of the gene 10 protein (gene 10), SAG1, SAG2, SAG3, SRS1, P54, mixture of the five fusion proteins (Mix) or TL. Mix included 20 µg of SAG1, SAG2, SAG3, SRS1 and P54 each. The interval between the 2 injections was 14 days. Freund's complete (FCA) and incomplete adjuvant (Difco, MI) were used at the first and second immunization, respectively.
Challenge infection : The mice were intraperitoneally infected with 300 fresh Beverley bradyzoites suspended in 0.5 mL PBS, 14 days after the second immunization. Survivors were sacrificed and examined for tissue cysts in their brain 4 months after the infection. PBS was added to 3 ml of brain, and the mixture was homogenized and kept on ice. Three 10 µl spots of the brain suspension were examined with a microscope. The entire volume of the remaining homogenate was i.p. injected to 3 SPF mice. The mice were examined for Toxoplasma infection by serological analysis.
Immunofluorescense assay: RH strain tachyzoites were applied to a slide glass. The slides were fixed in cold acetone and treated with 1:200 dilution of anti-SAG1, SAG2, SAG3, SRS1 or P54 hyperimmune serum at 37°C for 1 hr. The hyperimmune serum was collected from the mice which received 3 or 4 immunizations with the E. coli-produced fusion proteins. After the serum was washed off, the slides were treated with fluorescein isothiocyanate (FITC) conjugated anti-mouse-IgM+G+A(H+L) antibodies (Southern Biotechnology, AL) and counterstained with propidium iodide. Serum reactivity was assayed by a fluorescence conforcal laser microscopy. Enzyme-linked immunosorbent assay (ELISA) measurements: Serum collected 13 days after the second immunization was analyzed for anti-Toxoplasma IgG1 and IgG2a levels by ELISA. The RH tachyzoites suspension were freeze-thawed, ultrasonicated and diluted to equivalence of 5 × 10 5 cells/ml with 0.05 M carbonate-bicarbonate buffer (pH 9.6) and the diluent was dispensed to the ELISA plates (Immunoplate MaxiSorp, Nunc, Denmark) in 50 µl aliquot per well. Bovine serum albumin (BSA)-dispensed wells were also prepared for a negative control. The plates were blocked, reacted with the serum in duplicate wells (50 µL/ well, 1:400 dilution by PBS) and recognized by 1,000-fold horseradish peroxidase (HRPO)-conjugated anti-mouse IgG1 or IgG2a antibodies (Bethyl, TX). All the plates were treated at 4°C overnight. Thereafter, the plates were stained with ABTS substrate (Sigma, MO). Absorption at 415 nm was measured with a microplate reader (MTP120, Corona Electric, Japan) and IgG levels were determined by subtraction of negative control value.
Western blotting : RH tachyzoites lysed in SDSPAGE sample buffer were run on polyacrylamide gels. The volume applied to each lane was equivalent to 6.5 × 10 4 tachyzoite cells. The samples were transferred onto polyvinylidene difluoride membranes (Immobiron P, Millipore Japan, Japan). The membranes were immersed in diluted sera (1:200) from each group collected 13 days after the second immunization and 3 months after the challenge. Then, the membranes were probed for IgG with Picoblue immunoscreening systems (Stratagene, CA).
Statistical Analysis : Serum IgG1 and IgG2a levels of each experimental group were compared with those of the gene 10-immunized group by Mann-Whitney U test. Daily survival rate was compared by chi-square method to background data from 12 weeks old female BALB/c mice immunized with gene 10 antigens and i.p. challenged with 300 bradyzoites of the Beverley strain.
RESULTS
Sequence analysis: Some base substitutions were observed in the recombinant DNA expressing the fusion proteins when compared to the previously reported sequences of T. gondii RH strain (GeneBank accession number M23658, M33572, L21720, U77677 and S54994 for SAG1, SAG2, SAG3, SRS1 and P54, respectively). There were 2 substitutions in the SAG1 and 1 substitution in the SAG2, which did not affect protein sequences (data not shown). There were some substitutions in the SAG3 sequence at 472P475 bp (CTCA→ACTC) and at 623-624 bp (GC→CG), resulting in Leu,Lys→Thr,Gln and Gly→Ala, respectively. The SAG3 sequence included another substitution which did not affect amino acids (data not shown). There was 1 substitution in the SRS1 at 459 bp (A→G) and in the P54 at 653 bp (A→G) respectively, which were responsible for Asn→Ser and Met→Val.
Antibody responses against T. gondii: To evaluate whether the recombinant antigens could induce antibodies that recognize natural antigens of T. gondii, mouse hyperimmune serum induced by the recombinant SAG1, SAG2, SAG3, SRS1 and P54 were examined against T. gondii tachyzoites by an immunofluorescense assay. All the hyperimmune sera recognized tachyzoites, although signal strength was different among the antigens (Fig. 1) .
To examine anti-Toxoplasma IgG1 and IgG2a induction by two i.p. immunizations, serum IgG levels against cell lysate of RH tachyzoites were determined by ELISA (Table  1) . No positive relation was found between the IgG levels and survival of mice. Gene10-immunization with FCA increased anti-Toxoplasma IgG1 and IgG2a values from less than 0.1 to 0.2. FCA might induce cross-reactive antibodies to tachyzoites. Mean IgG1 and IgG2a levels after SAG1-, SAG2-and SRS1-immunization were higher than 0.2, but statistical significance was not found. Anti-Toxoplasma IgG1/IgG2a proportions were equivalent among the groups.
To evaluate specific events induced by immunization and infection, post-immunization and convalescent sera collected 1 day before challenge and 3 months after challenge, respectively, were analyzed by Western blotting (Fig. 2) . Post-immunization sera from P54-immunized mice apparently recognized 2 antigens of tachyzoites. Molecular mass of the 2 antigens were calculated at approximately 55 kDa and 61 kDa on the basis of migration. After infection, sera from SAG2-immunized mice strongly recognized a 22 kDa antigen and those from P54-immunized mice recognized the two antigens again. Recognition patterns of sera from TLimmunized mice and positive sera from non-immunized mice were very similar to each other. Both sera recognized various antigens, especially an 30 kDa antigen but scarcely or did not react to 22 nor 55 kDa antigen. The 22, 30 and 55 kDa antigens corresponded to SAG2, SAG1 and P54 respectively, in accordance with the calculated molecular mass. No apparent reactions were observed in sera from SRS1-nor Mix-immunized mice. Survival: Acute experimental toxoplasmosis was apparently observed in each mouse. One week after the challenge, movement of the mice lowered and the coat became harsh during a few days. Thereafter, a few of SAG2-, SRS1, P54-or Mix-immunized mice recovered from the symptoms and survived, while the others did not recover and died. Milder symptoms were observed in TL-immunized group. However, the survivors gradually decreased in number in TL-immunized group during the experiment period. Accumulative mortality in SAG2-, SRS1-, Mix-or TLimmunized groups was significantly lower in comparison with the background ( Table 2) .
Tissue cyst formation: Tissue cysts were not detected in the brain of survivors immunized with the recombinant antigens 4 months after the challenge, whereas 2,000 or more cysts were observed in the brain of TL-immunized mice (Table 3) . Further, none of the mice received the brain homogenates of mice immunized with recombinant antigen showed sero-positive responses by ELISA (0.1>IgG1 and IgG2a value) 2 months after the injection.
DISCUSSION
The most important effect in the present study is the improvement of survival of mice and cyst formation probably by specific antibody boosted by immunization with recombinant antigens followed by Toxoplasma infection. Although the survival rate was insufficiently raised by a recombinant vaccine, the rate increased by SRS1 (25%) is almost equivalent to that by the most successful SAG1 vaccine produced by E. coli, which increased by 24% on day 11 after infection [20] . No brain cyst was detected in all the 8 mice vaccinated with SAG2, SRS1, P54 or Mix after the infection with the lethal dose of T. gondii tachyzoites. Recombinant SAG1 supplemented with IL-12 decreases brain cyst formation by 40% [13] . TL-immunization extensively increased the anti-Toxoplasma IgG levels and almost completely reduced the mortality within 2 weeks after infection. The convalescent sera from TL mice showed the most predominant reaction to SAG1 of all the tachyzoite antigens, but the survivors had gradually decreased in number during the observation period of 4 months. SAG2-, SRS1-, P54-or Mix-immunization induced slight or no anti-SAG1 IgG levels after infection, but completely protected mice from death 12 days after infection. The observation suggests that anti-SAG1 IgG is not a critical protective factor against the chronic phase of infection. T. gondii can modulate the host immunity between the acute and chronic stages of infection through a modification of the isotypic distribution of antibodies [18] . Anti-SAG1 IgG may play a protective role mainly in the acute phase. Another explanation is that extensive levels of IgG may accelerate the parasite escape from the host immune system. This hypothesis partially supports an investigation describing the development of latency in Toxoplasma infection by previous immunization [31] .
Many studies have expected SAG1 to be the most effective anti-Toxoplasma immunogen. The importance of SAG1 in generating protective immunity has been strongly supported by the evidence that SAG1 transgenic mice, which endogenously express SAG1 and fall in congenital immune tolerance to SAG1, are more susceptible to T. gondii infection than normal mice [25, 26] . However, SAG1 did not protect mice from death in the present study. In the successful studies, anti-SAG1 IgG levels obviously increased before challenge [6, 11, 19, 20] . The failure in previous induction of anti-SAG1 IgG brought about the negative result of SAG1 vaccination in the present study. We demonstrated that the previous stimulation by SAG2 strongly boosted an induction of the specific IgG after infection and prevented the survivors from brain cyst formation, while TL stimulation induced slight IgG reaction to SAG2 and permitted cyst formation. This observation suggests that specific events against SAG2 can protect cyst formation. Because SAG2 depressed the lymphoproliferation [5] , the immunity against SAG2 reasonably modulate the protective effect in vivo.
The sera from SRS1-and Mix-immunized mice elicited no specific response in ELISA or Western blotting. Positive responses of anti-SAG1, SAG2, SAG3, SRS1 and P54 hyperimmune sera to the tachyzoites showed that all recombinant antigens can stimulate immunity against native Toxoplasma antigens. It is possible that sensitivity of the ELISA and Western blotting was insufficient to detect anti-SRS1 IgG induced by 2 doses of vaccination. The results from the survival and the Western blotting experiments with Mix and each antigen showed that mixed antigens provided no synergistic effect for the protection against lethal infection nor induction of IgGs.
T. gondii-reactive T-cell clone from an infected human produced a high level IFN-γ after a stimulation of P54 [23] . Numerous studies have suggested the importance of IFN-γ in protective immunity against Toxoplasma infection. Vaccination with P54 induced specific antibodies and the highest level of anti-Toxoplasma IgG. However, IgG2a, a good indicator of stimulated cellular immunity [7] , was not extensively increased after immunization with P54 and saved only 1 mouse from death. Since IgG1: IgG2a ratio of P54immunized mice was similar to that of other groups, the stimulation seems to be strongly affected by FCA rather than P54 itself.
Nielsen et al. [19] dramatically expanded a protective effect against the lethal infection by converting a SAG1 vaccine from the recombinant protein stimulating Th2 [20] to an intracellular expression system stimulating Th1. Immunization with a combination of recombinant SAG1 and IL-12, a Th1 driving cytokine, depressed the induction of anti-SAG1 IgG1 but reduced the brain parasite in comparison with immunization with SAG1 alone [13] . These previous studies demonstrated that Th1 stimulation is an accustomed strategy to elevate the efficacy of recombinant vaccines against Toxoplasma infection. This strategy might reinforce the protection induced by SAG2, SRS1 and P54.
